BC
APLS

Bayforest Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Bayforest Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,853
Closed -$472K – 790
2025
Q3 		$472K Sell
20,853
-35,786
-63% -$835K 0.22% 161
2025
Q2 		$980K Buy
56,639
+4,301
+8% +$79.6K 0.43% 38
2025
Q1 		$1.14M Buy
52,338
+42,499
+432% +$1.17M 0.5% 21
2024
Q4 		$314K Buy
+9,839
New +$296K 0.39% 33

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bayforest Capital's APLS Position: Q4 2025 in Review

Bayforest Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 20,853 shares — an estimated $472K sold.

Bayforest Capital first reported a position in APLS in Q4 2024 and held it in 4 quarters. The position peaked at $1.14M in Q1 2025. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Bayforest Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bayforest Capital sold 20,853 Apellis Pharmaceuticals shares in Q4 2025, an estimated $472K.
  • Bayforest Capital first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Bayforest Capital's Apellis Pharmaceuticals position peaked at $1.14M in Q1 2025.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Bayforest Capital's 13F filing for Q4 2025, filed 27 Jan 2026.